Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as
monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in
subjects platinum-sensitive and platinum-resistant ovarian cancer.